Research Paper Volume 15, Issue 19 pp 10501—10523
A SARS-CoV-2 related signature that explores the tumor microenvironment and predicts immunotherapy response in esophageal squamous cell cancer
Figure 8. Prediction of responsiveness to immunotherapy using our signature based on public database. (A) Prognostic differences between risk subgroups in the IMvigor210 cohort. (B) Differences among immunotherapy responses based on risk scores in the IMvigor210 cohort. (C) Distribution of immunotherapy responses based on risk subgroups in the IMvigor210 cohort. (D) Prognostic differences between risk subgroups based on early stage (stage I–II) in the IMvigor210 cohort. (E) Prognostic differences between risk subgroups based on advanced patients (stage III–IV) in the IMvigor210 cohort. (F) Prognostic differences between risk subgroups in the GSE78220 cohort. (G) Differences among immunotherapy responses based on risk scores in the GSE78220 cohort. (H) Distribution of immunotherapy responses based on risk subgroups in the GSE78220 cohort. (*P < 0.05).